Drug Trial Radar · NCT01363323
Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization
Last checked: Nov 19, 2026Latest source record: Nov 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
546
Actual
Start
Nov 2004
Primary completion
Jan 2005
Study completion Feb 2005
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 1, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will employ a single-center, randomized, double-blind parallel-group design for MNTX and placebo, with a positive control (moxifloxacin) dosed single-blind to confirm methodology, in normal healthy male and female volunteers. Multiple ECGs will be obtained after single clinical and supratherapeutic doses of MNTX to assess ECG effects compared to placebo.
Conditions
- Healthy Volunteers
Interventions
Methylnaltrexone (MNTX)Drug
Dose 1
Methylnaltrexone (MNTX)Drug
Dose 2
Methylnaltrexone (MNTX)Drug
Dose 3
PlaceboDrug
MoxifloxacinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effects of MNTX on QTcI durationTime frame: 3 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Progenics Pharmaceuticals
Tarrytown, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.